| Press releases

Formycon Reports First Half 2016 Financial and Operating Results

The development of Formycon’s biosimilar candidates has progressed well during the first half of 2016. The company announced this update as it unveiled its 2016 half-year figures.


German Equity Forum 2016

German Equity Forum 2016, November 21 – 23; Frankfurt/Main

Financial reports

Half-Year Report 2016

Published on 20. September 2016

  • buchner_en
  • pipeline-en-teaser
  • Foto_MedicineMaker_Powerlist
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.